@article{b379c58a25854f3fb011c33052cffadc,
title = "Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology",
abstract = "Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.",
keywords = "CARDIOVASCULAR OUTCOMES, Cardiovascular outcomes, DAPAGLIFLOZIN, DIABETES-MELLITUS, EMPAGLIFLOZIN, Heart failure, KIDNEY-DISEASE, MORTALITY, Quality of life, RATIONALE, RESISTANCE, SERUM URIC-ACID, SGLT2 INHIBITORS, Sodium-glucose co-transporter 2 inhibitors, Type 2 diabetes mellitus, MECHANISM",
author = "Seferovic, {Petar M.} and Gabriele Fragasso and Mark Petrie and Wilfried Mullens and Roberto Ferrari and Thomas Thum and Johann Bauersachs and Anker, {Stefan D.} and Robin Ray and Yuksel Cavusoglu and Marija Polovina and Marco Metra and Giuseppe Ambrosio and Krishna Prasad and Jelena Seferovic and Jhund, {Pardeep S.} and Giuseppe Dattilo and Jelena Celutkiene and Massimo Piepoli and Brenda Moura and Ovidiu Chioncel and {Ben Gal}, Tuvia and Stefan Heymans and {de Boer}, {Rudolf A.} and Tiny Jaarsma and Loreena Hill and Yuri Lopatin and Lyon, {Alexander R.} and Piotr Ponikowski and Mitja Lainscak and Ewa Jankowska and Christian Mueller and Francesco Cosentino and Lars Lund and Filippatos, {Gerasimos S.} and Frank Ruschitzka and Coats, {Andrew J. S.} and Rosano, {Giuseppe M. C.}",
note = "Funding Information: P.M.S. reports Medtronic, Abbott, Servier, AstraZeneca, and Respicardia honoraria for lecture; Boehringer Ingelheim and Novartis consultancy agreement and honoraria for lecture; Vifor Pharma consultancy agreement. M.P. reports grants and personal fees from AstraZeneca, Novartis, NovoNordisk, Boehringer Ingelheim, Abbvie, Takeda, Bayer, Pharmacosmos; personal fees from Vifor, Cardiorentis, Alnylam, outside the submitted work. R.F. reports personal fees from Servier International, Merck Serono, Pfizer, Doc Generici, Societ{\`a} Prodotti Antibiotici SpA; grants and personal fees from Novartis, outside the submitted work; T.T. reports personal fees and other from Cardior Pharmaceuticals GmbH, outside the submitted work. J.B. reports personal fees from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, MSD, Novartis, Pfizer, Servier; grants and personal fees from Abiomed, CvRX, Vifor, Zoll, outside the submitted work. M.P. reports Boehringer Ingelheim honorarium for lecture, outside the submitted work. M.M. reports personal fees for minimal amount honoraria from AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Vifor Pharma for participation to trials' committees or public speeches, outside the submitted work. J.{\v C}. reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Amgen, outside the submitted work. R.A.d.B. reports grants from Abbott, AstraZeneca, Bristol‐Myers Squibb, Novartis, NovoNordisk, Roche; personal fees from Abbott, AstraZeneca, Novartis, Roche, outside the submitted work. L.H. reports personal fees from Novartis, outside the submitted work. A.R.L. reports personal fees from Ferring Pharmaceuticals, Eli Lily, Bristol‐Myers Squibb, Eisai Ltd, Myocardial Solutions and Heartfelt Technologies. C.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, outside the submitted work. L.H.L. reports personal fees from Merck, Sanofi, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia; grants and personal fees from Vifor‐Fresenius, AstraZeneca, Relypsa, Novartis, Mundipharma, Boehringer Ingelheim; grants from Boston Scientific, outside the submitted work. G.S.F. reports other from Committee Member in trials sponsored by Medtronic, Vifor, Servier, Novartis, BI, outside the submitted work. F.R. since 1st January 2018: no personal payments/all payments directly to the University of Zurich; before 2018: reports grants and personal fees from SJM/Abbott, Servier, Novartis, Bayer; personal fees from Zoll, AstraZeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche, Cardiorentis, Boehringer Ingelheim, other from Heartware, grants from Mars, outside the submitted work. F.C. reports personal fees from NovoNordisk, MSD, Pfizer, Mundipharma, Lilly, AstraZeneca, BMS, outside the submitted work. A.J.S.C. reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia, outside the submitted work. S.D.A. reports grants and personal fees from Vifor Int, Abbott Vascular; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Impulse Dynamics, Cardiac Dimensions, outside the submitted work. P.P. reports personal fees and other from Boehringer Ingelheim, AstraZeneca, during the conduct of the study; personal fees and other from Amgen, Novartis, Servier, Bayer, BMS, Vifor Pharma, Renal Guard Solutions, Impulse Dynamics; personal fees from Pfizer, Berlin Chemie, outside the submitted work. B.M. reports personal fees from Boehringer Ingelheim, AstraZeneca, outside the submitted work. M.L. reports personal fees from AstraZeneca, Boehringer Ingelheim, during the conduct of the study. All other authors have nothing to disclose. Conflict of interest: Publisher Copyright: {\textcopyright} 2020 European Society of Cardiology",
year = "2020",
month = sep,
doi = "10.1002/ejhf.1954",
language = "English",
volume = "22",
pages = "1495--1503",
journal = "European journal of heart failure",
issn = "1388-9842",
publisher = "Wiley",
number = "9",
}